Encapsidation of APOBEC3G into HIV-1 virions involves lipid raft association and does not correlate with APOBEC3G oligomerization

Retrovirology

Volumn 6, Issue , 2009, Pages 99-

  Khan, Mohammad A ^a   Goila Gaur, Ritu ^a   Kao, Sandra ^a   Miyagi, Eri ^a   Walker Jr, Robert C ^a   Strebel, Klaus ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; EPITOPE; GENOMIC RNA;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL FRACTIONATION; CONTROLLED STUDY; GENE INTERACTION; GENE MUTATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; LIPID RAFT; MUTANT; NONHUMAN; OLIGOMERIZATION; RNA BINDING; VIRUS CAPSID; VIRUS GENOME;

AMINO ACID SUBSTITUTION; CELL FRACTIONATION; CYTIDINE DEAMINASE; HIV-1; HUMANS; IMMUNOPRECIPITATION; MEMBRANE MICRODOMAINS; MUTANT PROTEINS; MUTATION, MISSENSE; PROTEIN BINDING; RNA, VIRAL; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 70749116130     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-99     Document Type: Article

References (43)

1. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418:646-650. 10.1038/nature00939, 12167863.
2. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008, 5:51. 2443170, 18577210, 10.1186/1742-4690-5-51.
3. Miller JH, Presnyak V, Smith HC. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G. Retrovirology 2007, 4:81. 2222665, 18036235, 10.1186/1742-4690-4-81.
4. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79:285-296. 10.1006/geno.2002.6718, 11863358.
5. Iwatani Y, Takeuchi H, Strebel K, Levin JG. Biochemical Activities of Highly Purified, Catalytically Active Human APOBEC3G: Correlation with Antiviral Effect. J Virol 2006, 80:5992-6002. 1472592, 16731938, 10.1128/JVI.02680-05.
6. Yu Q, Konig R, Pillai S, Chiles K, Kearney M, Palmer S, Richman D, Coffin JM, Landau NR. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004, 11:435-442. 10.1038/nsmb758, 15098018.
7. Khan MA, Kao S, Miyagi E, Takeuchi H, Goila-Gaur R, Opi S, Gipson CL, Parslow TG, Ly H, Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. J Virol 2005, 79:5870-5874. 1082784, 15827203, 10.1128/JVI.79.9.5870-5874.2005.
8. Khan MA, Goila-Gaur R, Opi S, Miyagi E, Takeuchi H, Kao S, Strebel K. Analysis of the contribution of cellular and viral RNA to the packaging of APOBEC3G into HIV-1 virions. Retrovirology 2007, 4:48. 1948019, 17631688, 10.1186/1742-4690-4-48.
9. Wang T, Tian C, Zhang W, Luo K, Sarkis PT, Yu L, Liu B, Yu Y, Yu XF. 7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G. J Virol 2007, 81:13112-13124. 2169093, 17881443, 10.1128/JVI.00892-07.
10. Tian C, Wang T, Zhang W, Yu XF. Virion packaging determinants and reverse transcription of SRP RNA in HIV-1 particles. Nucleic Acids Res 2007, 35:7288-7302. 2175372, 17959647, 10.1093/nar/gkm816.
11. Wang T, Tian C, Zhang W, Sarkis PT, Yu XF. Interaction with 7SL RNA but not with HIV-1 genomic RNA or P bodies is required for APOBEC3F virion packaging. J Mol Biol 2008, 375:1098-1112. 10.1016/j.jmb.2007.11.017, 18067920.
12. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 2004, 279:33177-33184. 10.1074/jbc.M402062200, 15159405.
13. Schafer A, Bogerd HP, Cullen BR. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004, 328:163-168. 10.1016/j.virol.2004.08.006, 15464836.
14. Alce TM, Popik W. APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 2004, 279:34083-34086. 10.1074/jbc.C400235200, 15215254.
15. Zennou V, Perez-Caballero D, Gottlinger H, Bieniasz PD. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. J Virol 2004, 78:12058-12061. 523273, 15479846, 10.1128/JVI.78.21.12058-12061.2004.
16. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114:21-31. 10.1016/S0092-8674(03)00515-4, 12859895.
17. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424:99-103. 10.1038/nature01709, 12808466.
18. Burnett A, Spearman P. APOBEC3G Multimers Are Recruited to the Plasma Membrane for Packaging into Human Immunodeficiency Virus Type 1 Virus-Like Particles in an RNA-Dependent Process Requiring the NC Basic Linker. J Virol 2007, 81:5000-5013. 1900209, 17344295, 10.1128/JVI.02237-06.
19. Douaisi M, Dussart S, Courcoul M, Bessou G, Vigne R, Decroly E. HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun 2004, 321:566-573. 10.1016/j.bbrc.2004.07.005, 15358144.
20. Luo K, Liu B, Xiao Z, Yu Y, Yu X, Gorelick R, Yu XF. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol 2004, 78:11841-11852. 523292, 15479826, 10.1128/JVI.78.21.11841-11852.2004.
21. Navarro F, Bollman B, Chen H, Konig R, Yu Q, Chiles K, Landau NR. Complementary function of the two catalytic domains of APOBEC3G. Virology 2005, 333:374-386. 10.1016/j.virol.2005.01.011, 15721369.
22. Opi S, Takeuchi H, Kao S, Khan MA, Miyagi E, Goila-Gaur R, Iwatani Y, Levin JG, Strebel K. Monomeric APOBEC3G is catalytically active and has antiviral activity. J Virol 2006, 80:4673-4682. 1472092, 16641260, 10.1128/JVI.80.10.4673-4682.2006.
23. Huthoff H, Malim MH. Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation. J Virol 2007, 81:3807-3815. 1866099, 17267497, 10.1128/JVI.02795-06.
24. Bach D, Peddi S, Mangeat B, Lakkaraju A, Strub K, Trono D. Characterization of APOBEC3G binding to 7SL RNA. Retrovirology 2008, 5:54. 2494554, 18597676, 10.1186/1742-4690-5-54.
25. Gooch BD, Cullen BR. Functional domain organization of human APOBEC3G. Virology 2008, 379:118-124. 2601658, 18639915, 10.1016/j.virol.2008.06.013.
26. Zhang KL, Mangeat B, Ortiz M, Zoete V, Trono D, Telenti A, Michielin O. Model Structure of Human APOBEC3G. PLoS ONE 2007, 2:e378. 1849894, 17440614, 10.1371/journal.pone.0000378.
27. Bogerd HP, Doehle BP, Wiegand HL, Cullen BR. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 2004, 101:3770-3774. 374319, 14999100, 10.1073/pnas.0307713101.
28. Schrofelbauer B, Chen D, Landau NR. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 2004, 101:3927-3932. 374346, 14978281, 10.1073/pnas.0307132101.
29. Mangeat B, Turelli P, Liao S, Trono D. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 2004, 279:14481-14483. 10.1074/jbc.C400060200, 14966139.
30. Xu H, Svarovskaia ES, Barr R, Zhang Y, Khan MA, Strebel K, Pathak VK. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 2004, 101:5652-5657. 397464, 15054139, 10.1073/pnas.0400830101.
31. Stenglein MD, Matsuo H, Harris RS. Two regions within the amino-terminal half of APOBEC3G cooperate to determine cytoplasmic localization. J Virol 2008, 82:9591-9599. 2546964, 18667511, 10.1128/JVI.02471-07.
32. Huthoff H, Autore F, Gallois-Montbrun S, Fraternali F, Malim MH. RNA-dependent oligomerization of APOBEC3G is required for restriction of HIV-1. PLoS Pathog 2009, 5:e1000330. 2646141, 19266078, 10.1371/journal.ppat.1000330.
33. Karczewski MK, Strebel K. Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol 1996, 70:494-507. 189838, 8523563.
34. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003, 77:11398-11407. 229358, 14557625, 10.1128/JVI.77.21.11398-11407.2003.
35. Opi S, Kao S, Goila-Gaur R, Khan MA, Miyagi E, Takeuchi H, Strebel K. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. J Virol 2007, 81:8236-8246. 1951302, 17522211, 10.1128/JVI.02694-06.
36. Roos JW, Maughan MF, Liao Z, Hildreth JE, Clements JE. LuSIV cells: a reporter cell line for the detection and quantitation of a single cycle of HIV and SIV replication. Virology 2000, 273:307-315. 10.1006/viro.2000.0431, 10915601.
37. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 2001, 98:13925-13930. 61143, 11717449, 10.1073/pnas.241320298.
38. Bogerd HP, Cullen BR. Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation. RNA 2008, 14:1228-1236. 2390788, 18456846, 10.1261/rna.964708.
39. Wang T, Zhang W, Tian C, Liu B, Yu Y, Ding L, Spearman P, Yu XF. Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C. Virology 2008, 377:71-79. 2692739, 18495196, 10.1016/j.virol.2008.04.012.
40. Zhang L, Li X, Ma J, Yu L, Jiang J, Cen S. The incorporation of APOBEC3 proteins into murine leukemia viruses. Virology 2008, 378:69-78. 10.1016/j.virol.2008.05.006, 18572219.
41. Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K. Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity. Retrovirology 2007, 4:61. 2018723, 17727729, 10.1186/1742-4690-4-61.
42. Svarovskaia ES, Xu H, Mbisa JL, Barr R, Gorelick RJ, Ono A, Freed EO, Hu WS, Pathak VK. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. J Biol Chem 2004, 279:35822-35828. 10.1074/jbc.M405761200, 15210704.
43. Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Pathog 2007, 3:e15. 1796622, 17291161, 10.1371/journal.ppat.0030015.